BIOMARKER:

MSI-H/dMMR

News alerts, weekly reports and conference planners

Related biomarkers:

‹

›

MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline Front Oncol - 1 week (New C4) pembrolizumab Sensitive : A2 Front Oncol - 1wk	pembrolizumab Sensitive: A2 - Guideline Front Oncol - 1 week pembrolizumab Sensitive : A2 Front Oncol - 1 week - (New C4)
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	dostarlimab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) dostarlimab Sensitive : A1 ESMO 2022 - 3wk	dostarlimab Sensitive: A1 - Approval ESMO 2022 - 3 weeks dostarlimab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) pembrolizumab Sensitive : A1 ESMO 2022 - 3wk	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks pembrolizumab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	dostarlimab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) dostarlimab Sensitive : A1 ESMO 2022 - 3wk	dostarlimab Sensitive: A1 - Approval ESMO 2022 - 3 weeks dostarlimab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) pembrolizumab Sensitive : A1 ESMO 2022 - 3wk	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks pembrolizumab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) nivolumab + ipilimumab Sensitive : A2 ESMO 2022 - 3wk	nivolumab + ipilimumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks nivolumab + ipilimumab Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Gastrointestinal Cancer	MSI-H/dMMR	Gastrointestinal Cancer	dostarlimab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) dostarlimab Sensitive : C1 ESMO 2022 - 3wk	dostarlimab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks dostarlimab Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	durvalumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) durvalumab Sensitive : C2 ESMO 2022 - 3wk	durvalumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks durvalumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	avelumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) avelumab Sensitive : C2 ESMO 2022 - 3wk	avelumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks avelumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
MSI-H/dMMR	Biliary Tract Cancer	MSI-H/dMMR	Biliary Tract Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
MSI-H/dMMR	Peritoneal Cancer	MSI-H/dMMR	Peritoneal Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Esophageal Cancer	MSI-H/dMMR	Esophageal Cancer	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : C1	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : C1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : A2	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : A2
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2
MSI-H/dMMR	Fallopian Tube Cancer	MSI-H/dMMR	Fallopian Tube Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Maxillary Sinus Carcinoma	MSI-H/dMMR	Maxillary Sinus Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Penile Cancer	MSI-H/dMMR	Penile Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
MSI-H/dMMR	Ovarian Cancer	MSI-H/dMMR	Ovarian Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Germ Cell Tumors	MSI-H/dMMR	Germ Cell Tumors	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2
MSI-H/dMMR	Rectal Cancer	MSI-H/dMMR	Rectal Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
MSI-H/dMMR	Neuroendocrine Tumor	MSI-H/dMMR	Neuroendocrine Tumor	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Pancreatic Adenocarcinoma	MSI-H/dMMR	Pancreatic Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Cervical Cancer	MSI-H/dMMR	Cervical Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Chordoma	MSI-H/dMMR	Chordoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Ewing Sarcoma	MSI-H/dMMR	Ewing Sarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Osteosarcoma	MSI-H/dMMR	Osteosarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Breast Cancer	MSI-H/dMMR	Breast Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2

MSI-H/dMMR

Associations